UCB stock pre-market at EUR 205.50: plus 0.10 percent
Published on 10/01/2026 at 07:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock was at EUR 205.50 pre-market at 7:42 a.m. CEST on October 1, 2026, according to Lang & Schwarz. That was plus 0.10 percent versus the Lang & Schwarz prior close of EUR 205.30 on September 30, 2026.
UCB stock before the Xetra open
The Lang & Schwarz bid was EUR 204.90 and the ask was EUR 206.10. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.
Myasthenia gravis data on the agenda
In a release dated September 29, 2026, UCB said it would present data from its myasthenia gravis portfolio at the AANEM Congress Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session in Orlando from September 29 to October 2, 2026.
The company said the presentations include post hoc analyses of minimal symptom expression in generalized myasthenia gravis patients receiving zilucoplan or rozanolixizumab. UCB also said interim data on cizutamig, an investigational BCMA×CD3 T-cell engager, would be presented in a Phase 1b study.
